Omnicell, Inc. Revises Its Earnings Guidance for the Fiscal Year of 2020 and Full Year of 2021
January 13, 2021 at 08:01 am
Share
Omnicell, Inc. revised its earnings guidance for the Fiscal year of 2020 and full year of 2021. For the period, the company expects 2020 product bookings to be approximately $1.00 billion, exceeding its prior guidance of $865 million-$900 million. The Company expects 2020 total revenues to be $890 million-$892 million, exceeding its prior guidance of $881 million-$887 million. The Company expects 2020 GAAP net income to be $28.6 million-$30.6 million.
For the full year of 2021, the company expects total revenues to be between $1.085 billion and $1.105 billion, an increase from preliminary guidance provided on October 27, 2020.
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Companyâs XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.